Citryll completes patient dosing in the repeat dose stage of the Phase 1 trial for the novel anti-inflammatory candidate CIT-013
Pivot Park is proud of our tenant, Citryll, for successfully completing patient dosing in the repeat dose stage of their Phase 1 trial for the innovative anti-inflammatory candidate, CIT-013. This significant milestone underscores Citryll’s dedication to advancing treatments for immune-mediated inflammatory diseases. We are thrilled to follow their journey and look forward to the promising results expected later this year, paving the way for Phase 2a trials. Well done, Citryll!
Read the full press release here.
Find more news here.


